Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450

被引:129
作者
Sai, Y
Dai, R
Yang, TJ
Krausz, KW
Gonzalez, FJ
Gelboin, HV
Shou, M
机构
[1] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA
[2] NCI, Mol Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA
[3] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1080/004982500237541
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The selectivity of eight chemical inhibitors has been extensively evaluated with 10 cDNA-expressed human cytochrome P450 isoforms (CYP). The results indicate that sulphaphenazole, quinidine and alpha-naphthoflavone are selective inhibitors of CYP2C9 (IC50 = 0.5-0.7 mu M), CYP2D6 (0.3-0.4 mu M) and CYP1A (0.05-5 mu M) respectively on the basis of the IC50, which are much lower than those of other P450 isoforms (> 10-fold). 2. Ketoconazole exhibited potent inhibition of both CYP3A4-catalysed metabolism of phenanthrene, testosterone, diazepam (IC50 = 0.03-0.5 mu M) and CYP1A1-calalysed deethylation of 7-ethoxycoumarin (0.33 mu M). The selectivity of ketoconazole for other P450s was highly related to the concentration used. 3. Diethyldithiocarbamate, orphenadrine and furafylline were shown separately to be less selective inhibitors of CYP2E1, CYP2B6 and CYP1A isoforms by a broad range of IC50 that overlap those observed with other P450 isoforms. 4. Furafylline, quinidine and alpha-naphthoflavone activated CYP3A4-catalysed phenanthrene metabolism by 1.7-, 2- and 15-fold respectively. 5. The selectivity of orphenadrine and ketoconazole was further examined by using inhibitory monoclonal antibodies (MAb). Inhibitory MAb specific for the individual P-450 isoforms may be of greater value than chemical inhibitors.
引用
收藏
页码:327 / 343
页数:17
相关论文
共 42 条
  • [1] [Anonymous], ADV FLAVONOID RES
  • [2] INVITRO INHIBITION STUDIES OF TOLBUTAMIDE HYDROXYLASE-ACTIVITY OF HUMAN-LIVER MICROSOMES BY AZOLES, SULFONAMIDES AND QUINOLINES
    BACK, DJ
    TJIA, JF
    KARBWANG, J
    COLBERT, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (01) : 23 - 29
  • [3] KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9
    BALDWIN, SJ
    BLOOMER, JC
    SMITH, GJ
    AYRTON, AD
    CLARKE, SE
    CHENERY, RJ
    [J]. XENOBIOTICA, 1995, 25 (03) : 261 - 270
  • [4] EXPRESSION OF P1-450 AND P3-450 DNA CODING SEQUENCES AS ENZYMATICALLY ACTIVE CYTOCHROMES-P-450 IN MAMMALIAN-CELLS
    BATTULA, N
    SAGARA, J
    GELBOIN, HV
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (12) : 4073 - 4077
  • [5] Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam
    Bonnabry, P
    Leemann, T
    Dayer, P
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) : 305 - 308
  • [6] Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321
  • [7] CHANG TKH, 1993, CANCER RES, V53, P5629
  • [8] EVALUATION OF TRIACETYLOLEANDOMYCIN, ALPHA-NAPHTHOFLAVONE AND DIETHYLDITHIOCARBAMATE AS SELECTIVE CHEMICAL PROBES FOR INHIBITION OF HUMAN CYTOCHROMES P450
    CHANG, TKH
    GONZALEZ, FJ
    WAXMAN, DJ
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 311 (02) : 437 - 442
  • [9] GELBOIN HV, 1993, PHARMACOL REV, V45, P413
  • [10] Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4
    Gelboin, HV
    Krausz, KW
    Goldfarb, I
    Buters, JTM
    Yang, SK
    Gonzalez, FJ
    Korzekwa, KR
    Shou, MG
    [J]. BIOCHEMICAL PHARMACOLOGY, 1995, 50 (11) : 1841 - 1850